HPK1 Antibody (G-8): sc-376103
- HPK1 Antibody (G-8) is a mouse monoclonal IgG2a κ provided at 200 µg/ml
- specific for an epitope mapping between amino acids 4-31 at the N-terminus of HPK1 of human origin
- recommended for detection of HPK1 of mouse, rat and human origin by WB, IP, IF and ELISA; also reactive with additional species, including and canine, bovine and porcine
- m-IgG Fc BP-HRP, m-IgG2a BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for HPK1 Antibody (G-8) for WB applications. These reagents are now offered in bundles with HPK1 Antibody (G-8) (see ordering information below).
QUICK LINKS
HPK1 Antibody (G-8) is a mouse monoclonal IgG2a antibody that detects HPK1 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). HPK1, or hematopoietic progenitor kinase 1, is a crucial serine/threonine kinase that plays a significant role in the regulation of the c-Jun N-terminal kinase (JNK) signaling pathway, which is vital for cellular responses to stress and inflammation. By phosphorylating MEKK, HPK1 acts as a key regulator in the activation of the JNK/SAPK pathway, influencing various cellular processes including apoptosis, differentiation, and proliferation. Proper functioning of HPK1 is essential for maintaining cellular homeostasis and responding to external stimuli, making HPK1 a critical component in the signaling networks that govern cell fate decisions. Anti-HPK1 antibody (G-8) serves as an invaluable tool for researchers exploring the intricate mechanisms of the JNK signaling pathway and its implications in various diseases, including cancer and neurodegenerative disorders.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
HPK1 Antibody (G-8) References:
- Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor. | You, D., et al. 2021. J Immunother Cancer. 9: PMID: 33408094
- The HPK1 Inhibitor A-745 Verifies the Potential of Modulating T Cell Kinase Signaling for Immunotherapy. | Malchow, S., et al. 2022. ACS Chem Biol. 17: 556-566. PMID: 35188729
- Discovery of Novel HPK1 Inhibitors Through Structure-Based Virtual Screening. | Ge, H., et al. 2022. Front Pharmacol. 13: 850855. PMID: 35370676
- Discovery of Macrocycle-Based HPK1 Inhibitors for T-Cell-Based Immunotherapy. | Wang, MS., et al. 2023. J Med Chem. 66: 611-626. PMID: 36542759
- An HPK1 inhibitor enhanced the tumour response to anti-PD-1 immunotherapy in non-Hodgkin's lymphoma. | Yang, L., et al. 2023. Clin Exp Med. 23: 3767-3780. PMID: 37106265
- Novel Diaminopyrimidine Carboxamides as HPK1 Inhibitors for Treating Cancer. | Sabnis, RW. 2023. ACS Med Chem Lett. 14: 899-900. PMID: 37465291
- Discovery of quinazoline HPK1 inhibitors with high cellular potency. | Toure, M., et al. 2023. Bioorg Med Chem. 92: 117423. PMID: 37531921
- Discovery of highly efficient CRBN-recruiting HPK1-PROTAC as a potential chemical tool for investigation of scaffolding roles in TCR signaling. | Zeng, S., et al. 2024. Bioorg Chem. 143: 107016. PMID: 38086239
- High HPK1+PD-1+TIM-3+CD8+ T cells infiltration predicts poor prognosis to immunotherapy in NSCLC patients. | Zhang, J., et al. 2024. Int Immunopharmacol. 127: 111363. PMID: 38101218
- Discovery of an Exceptionally Orally Bioavailable and Potent HPK1 PROTAC with Enhancement of Antitumor Efficacy of Anti-PD-L1 Therapy. | Wu, M., et al. 2024. J Med Chem. 67: 13852-13878. PMID: 39084610
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
HPK1 Antibody (G-8) | sc-376103 | 200 µg/ml | $322.00 | |||
HPK1 Antibody (G-8): m-IgG Fc BP-HRP Bundle | sc-537965 | 200 µg Ab; 10 µg BP | $361.00 | |||
HPK1 Antibody (G-8): m-IgGκ BP-HRP Bundle | sc-535460 | 200 µg Ab; 40 µg BP | $361.00 | |||
HPK1 Antibody (G-8): m-IgG2a BP-HRP Bundle | sc-548166 | 200 µg Ab; 10 µg BP | $361.00 | |||
HPK1 (G-8) Neutralizing Peptide | sc-376103 P | 100 µg/0.5 ml | $69.00 |